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Protocol
AbstrACt
Introduction Atrial ibrillation (AF) affects >6% of 
people aged 65 years or older. Left undetected and 
untreated, patients may develop signiicant cardiovascular 
complications and have a ivefold increased risk of 
suffering a stroke. For 40% of all sufferers, AF can be 
asymptomatic. Every year in the UK, £2.2 billion is spent on 
AF-related strokes, so there is an urgent need to improve 
early detection of AF. This study aims to determine the 
feasibility of using trained clinical pharmacists based in 
general practices, to screen for AF, using pulse palpation 
and a single-lead ECG device on participants aged 65 
years or older, attending inluenza vaccination clinics.
Methods and analysis Seven clinical pharmacists will 
be trained by a cardiologist to pulse palpate and record 
single-lead ECGs using the AliveCor Kardia Mobile device. 
Quantitative analysis will assess the accuracy and ability 
of the clinical pharmacist to identify pulse irregularities 
using pulse palpation and to record and interpret a single-
lead ECG. The level of agreement of pulse irregularities 
detected by pulse palpation will be compared with those 
detected by the single-lead ECG device, as will the level 
of agreement between the cardiologist and the device’s 
interpretation of the ECG. The proportion of people 
identiied with AF (conirmed by the cardiologist) will be 
determined. Additional demographic data will be obtained 
from all participants through a questionnaire. Qualitative 
data will be captured from the participants, from the 
clinical pharmacists and from the general practitioners and 
practice staff to determine their views on this method of 
AF screening. We aim to recruit 600 participants across 
general practices within Kent.
Ethics and dissemination This protocol was approved 
by the London–Riverside Research Ethics committee. The 
indings of this study will be disseminated through forums 
including, but not limited to, peer-reviewed journals, 
national and international conferences.
IntroduCtIon 
Atrial fibrillation (AF) is the most common 
sustained cardiac rhythm disorder and 
represents an urgent and significant global 
health challenge.1 AF is an age-related condi-
tion which affects ~6% of people over the 
age of 65 years, with an estimated >33 million 
people thought to be suffering with this condi-
tion globally.2 3 In the UK, AF affects ~2.5% of 
the population and >10% of people aged >80 
years.4 5 The lifetime risk of developing AF is 
1 in 4 for those >40 years compared with 1 in 
8 for breast cancer in age-matched women.6 7 
AF occurs when structural and/or electro-
physiological abnormalities alter atrial tissue 
to promote abnormal pulse formation and/
or propagation. The consequence of this 
is inefficient blood flow through the heart, 
resulting in an increased risk of clot forma-
tion. AF is frequently associated with other 
pathophysiological conditions, including, 
for example, hypertension, heart failure, 
obesity, diabetes, renal failure and stroke.8–10 
Untreated AF is associated with significant 
cardiovascular complications, a fivefold 
increased risk of stroke and a twofold risk 
of dementia (figure 1).11 12 Cardioembolic 
strokes arising from AF are often fatal (19%, 
strengths and limitations of this study
 Ź This is a single time-point screening study that 
combines with the inluenza vaccination clinics, to 
target a relevant at-risk proportion of the population 
(over 65 years), with an interest in their own personal 
well-being.
 Ź The screening strategy is likely to be convenient 
for patients and cost-effective when used in 
combination with current healthcare infrastructure 
and other patient services, such as the inluenza 
vaccination clinics.
 Ź The sample size of 600 will allow us to evaluate the 
proiciency and accuracy of the clinical pharmacist 
to screen patients for AF. It will also inform the 
design of any future large-scale screening studies.
 Ź Screening in combination with the inluenza 
vaccination season could prove disruptive to the 
clinics and recruiting patients on the day could be 
suboptimal.
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28-day mortality rate) and survivors have a 50% risk of 
severe disability.13 14 In the UK, approximately 20 000 
strokes occur as a result of AF each year.15 Strikingly, AF is 
often asymptomatic, with 40% of AF sufferers unaware of 
their condition and 25% of these asymptomatic patients 
present with stroke as their first symptom.16 17 In Kent, 
Surrey and Sussex, an observed prevalence of AF of 2.02% 
suggests that >65 000 people are living with undiagnosed 
AF across the region.18
The associated cost of AF-related strokes is significant. 
£2.2 billion is spent each year in the UK, corresponding 
to ~1% of the National Health Service (NHS) budget.19 
The costs can be expected to escalate further. The inci-
dence of AF has doubled since the last decade and is 
predicted to double again over the next 30 years.3 20–22 
Early detection of AF and treatment with oral anticoag-
ulants has been shown to significantly reduce the risk of 
stroke from an incidence of 3.9% to 1.3% and of death 
from 7.2% to 4.2%.23 Stroke avoidance through appro-
priate detection and treatment would save the NHS 
~£147 million a year.24 It has been proposed that in many 
cases a simple pulse check may be sufficient to detect 
AF.25 Despite evidence to show that appropriate oral 
anticoagulation significantly reduces the risk of stroke in 
patients with AF, 27% of these patients do not receive any 
treatment.26 Despite AF fulfilling all of the criteria, listed 
by the WHO, necessary to justify mass screening,27 28 there 
is still no international screening programme for AF.
A growing medical consensus backed by public health 
policy, agrees there is an urgent need to improve AF diag-
nosis before the first complications occur.29–31 Guidelines 
and initiatives directed at primary and secondary care 
(eg, European Society of Cardiology, National Institute 
for Health and Care Excellence (NICE) and Primary 
Care Atrial Fibrillation) have fallen short of the expected 
outcomes of early detection of AF, such as to reduce 
AF-related strokes.32–34 Interestingly, numerous oppor-
tunistic case findings of AF in patients in primary care 
(often alongside other screening initiatives for hyperten-
sion, diabetes and enhanced care services) and by various 
healthcare professionals (HCPs) have been reported.35–43 
In response to this, clinicians and policy-makers are 
now exploring primary care as an appropriate setting 
for improved AF diagnosis. This is likely to be conve-
nient for patients and cost-effective if used in combina-
tion with current healthcare infrastructure and other 
patient services such as influenza vaccination clinics.5 44 
In Medway and Kent, >65% of the people aged 65 years 
or older attend influenza vaccination clinics.45
The NHS Five Year Forward View focused on the need 
to provide integrated care for patients and placed a new 
focus on the prevention of ill health in order to keep 
the general public well.46 However, there are currently 
significant problems with patient access to general prac-
tice services and the heavy workload of general practi-
tioners (GPs) is currently under assessment by the NHS. 
It is widely recognised that pharmacists are an underused 
resource. The GP Workforce 10 Point Plan, Building 
the Workforce—the New Deal for General Practice, agreed 
in January 201547 aims to address immediate workload 
issues of GPs by building a workforce in new models 
of care, including the Clinical Pharmacist in General 
Practice scheme pilot, part funded by NHS England.48 
In this new workforce structure, the role of the expe-
rienced clinical pharmacist is to work alongside GPs 
as a member of the practice team, to reduce GP work-
load pressure by consulting with and treating patients 
directly. This pilot study aims to build on the successes 
of general practices that already employ clinical pharma-
cists either as part of their team or as partners. It will 
contribute to an evidence base to determine if clinical 
pharmacists can be involved in case-finding programmes 
for conditions which can have significant consequences 
if not identified. The need to develop an evidence base 
for pharmacists working within new models of care has 
been highlighted by the recent review into community 
pharmacy clinical services.49
This study aims to determine the feasibility of using 
trained clinical pharmacists based in general practices, 
to screen for AF, using pulse palpation and a single-lead 
ECG device. Using a single time point screening strategy 
which selectively targets the people aged >65 years 
attending influenza vaccination clinics, we aim to recruit 
a large and relevant (at-risk) study population for this 
initial study. In addition, we aim to evaluate the use of 
the AliveCor Kardia Mobile device compared with pulse 
palpation alone, as the latter is the current recommenda-
tion for screening.32 33
We hypothesise that trained clinical pharmacists, 
working in collaboration with GPs and using existing 
healthcare infrastructure, are ideally placed to undertake 
Figure 1 A summary of key reasons underlying the need 
for pilot clinical studies to support the development of the 
national atrial ibrillation screening programme in the UK led 
by general practice-based clinical pharmacists.
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an AF screening programme, within a primary care 
setting.
study population
Participants aged 65 years or older who are eligible for 
the influenza vaccination and are patients at one of the 
participating general practices will be invited to have 
a manual pulse check and a single-lead ECG using the 
AliveCor Kardia Mobile device with a clinical pharmacist 
who has been trained by the specialist study cardiologist 
to assess the rate and rhythm of the heart.
Persons excluded from the study will be anyone under 
the age of 65 years; patients aged ≥65 years, fitted with 
a pacemaker; with severe coexisting medical condition 
(eg, terminal illness); insufficient cognitive capacity (eg, 
severe dementia) to provide informed consent or who do 
not provide informed consent at the time of screening. 
Patients with already identified AF will not be excluded 
from the study, unless they have a pacemaker.
In Medway and Kent, <65% of the people over 65 years 
attend influenza vaccination clinics, making them an 
ideal setting for successful AF screening.45
recruitment
The screening study will be advertised by poster and 
leaflet within the participating practices, during October 
2017–January 2018; via text message and via verbal contact 
at the practice during the influenza vaccination clinics. 
There will be no charge for participation. Participants will 
be recruited using a consecutive sampling approach.
sample size
The prevalence of true AF detected among the screened 
participants aged 65 years or older using pulse palpation 
and a single-lead ECG is at least 5%,37 but may be as high 
as 10%.50 Assuming the lowest published estimate of 5%, a 
sample size of 600 would give 30 cases (95% CIs 22 to 38). 
With a minimum AF prevalence of 5%, at least 30 patients 
with AF would be expected to be identified from a sample 
size of 600 and this is sufficient to allow us to evaluate the 
proficiency and accuracy of clinical pharmacists to detect 
AF. This will inform the design and refinement of any 
future large-scale screening studies.
Clinical pharmacist recruitment
Clinical pharmacists will be recruited from a pool of clin-
ical pharmacists working within the Kent Community 
Health Trust, from pharmacists already embedded in 
participating practices and one clinical pharmacist will be 
provided by the Medway School of Pharmacy.
Clinical pharmacist training
All pharmacists will be offered pulse palpation and 
ECG training sessions in the evenings and at weekends 
with the study cardiologist. These sessions will occur at 
the Medway Maritime hospital on general cardiac wards 
and cardioversion clinics to expose them to a variety of 
patients. Training will also involve online ECG evaluation 
tests and presentations.
Quality processes
The accuracy of the pharmacist interpretation of the ECG 
will be continually monitored. Continued training and 
feedback will be offered throughout the study for those 
who require extra assistance. The pharmacist will be 
asked to fill in a training evaluation form at the end of the 
study in order to better inform future training sessions.
study practices
General practices will be recruited from the multispecialty 
community provider, Encompass, which is composed of 
13 medical practices across the Canterbury and Coastal 
clinical commissioning area including Whitstable, Faver-
sham, Canterbury, Ash and Sandwich in Kent.
Interventions
All eligible participants will be provided with a participant 
information leaflet (PIL) about the AF screening study, 
which will include information about the purpose of the 
study; what the screening process will involve; eligibility; 
what happens to the ECG and any collected data; what 
happens if they withdraw; what happens if they have AF; 
information about how to contact the investigators or to 
make a complaint and information about who is funding 
the study. Those who are interested will be either screened 
immediately or booked into another clinic at a later date. 
Those who are deemed eligible and proceed to screening 
will be assigned an information pack containing all the 
forms necessary for the session (demographic form, 
consent form, recording sheet, participant question-
naire and focus group invite) which will have assigned 
a patient ID code (excluding the participant satisfaction 
questionnaire and the focus group invite, which will be 
completely unidentifiable). The patient ID code, the 
patient name and date of birth will be recorded on a sheet, 
which will remain at the practice within the research 
study folder. This will allow participants who require any 
follow-up treatment to be identified from their patient ID 
number. The clinical pharmacist will provide them with 
a brief explanation of the procedure as outlined in the 
PIL, including management of data and verification of all 
ECGs by a specialist cardiologist and answer any questions 
that they may have. The participant will then be asked to 
provide informed written consent to the study, before the 
clinical pharmacist proceeds with the screening.
screening protocol
 Ź The screening process including all associated paper 
work should take on average 10–15 min and will follow 
the process outlined in figure 2.
 Ź The clinical pharmacist will ensure that the partic-
ipant understands what the study is about by taking 
them through the PIL, showing them the AliveCor 
Kardia Mobile device (figure 3) and answering any 
questions that the participant may have. They will 
then confirm if the patient wishes to proceed.
 Ź The clinical pharmacist will then take the participant 
through the consent form and ask them to initial all 
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boxes, with the exception of the focus groups partic-
ipation, which is optional. They will then be asked to 
date and sign the form, which will be countersigned 
by the clinical pharmacist. One copy will be retained 
by the practice and another will be given to the partic-
ipant to keep.
 Ź The clinical pharmacist will then fill in a basic demo-
graphic form with the participant (age, gender, 
ethnicity, height, weight, smoking and drinking 
habits).
 Ź The clinical pharmacist will then perform manual 
pulse palpation of the radial pulse for 30–60 s and 
record the number of beats per minute (bpm) and 
whether they felt the pulse was regular or irregular.
 Ź The clinical pharmacist will then use the AliveCor 
Kardia Mobile device to check the regularity and the 
bpm of the heart. To minimise noise they will ask 
any participants wearing hearing aids to temporarily 
switch them off and to remain silent while recording. 
The clinical pharmacist will then record a ≥30 s ECG. 
Only one ECG will be recorded unless the ECG was 
of poor quality, then a second ECG will be recorded.
 Ź The clinical pharmacist will assess the recorded ECG 
and explain to the participant what they can see. The 
clinical pharmacist will rate the quality of the recorded 
ECG (excellent, acceptable, poor or unreadable). 
They will then record if they can see P waves, if the P 
wave is followed by a QRS complex and if the intervals 
Figure 2 Pharmacists detecting atrial ibrillation study intervention low chart. AF, atrial ibrillation; GP, general practitioner; PIL, 
participant information lealet.
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between the QRS complexes are regularly spaced. 
They will then record whether they felt the ECG was 
normal sinus rhythm (SR), possible AF, unclassified 
(unreadable or potentially some other arrhythmia) 
or unreadable (ECG too poor to make any judge-
ment). The clinical pharmacist will also have space to 
write any additional comments about the ECG or the 
patient.
 Ź The clinical pharmacist will also record the device’s 
interpretation of the ECG (eg, normal, possible AF, 
unclassified or unreadable).
 Ź The clinical pharmacist will then provide the partic-
ipant with a letter (normal, possible AF and unclas-
sified/unreadable) dependent on their assessment 
of the ECG. They will reassure the participants that 
the cardiologist will over read all ECGs to confirm 
diagnosis and should there be any issues, they will 
be contacted by their practice. Participants assigned 
a possible AF or unclassified diagnosis will be 
contacted within 2 weeks by the practice to arrange 
any follow-up care (eg, 12-lead ECG) or to confirm 
that none is required (eg, if the participant is already 
on the register and receiving appropriate treatment). 
Participants who are assigned a normal diagnosis will 
only be contacted if the cardiologist thinks that this 
diagnosis is incorrect, otherwise they will expect no 
further contact. All participants with possible AF will 
also be given further information about AF before 
they leave in the form of a British Heart Foundation 
leaflet (‘Atrial Fibrillation Your Quick Guide’ and 
‘I’m in control of my Atrial fibrillation (AF)’).
 Ź All participants will then be asked to fill in a short 
participant questionnaire about the experience.
 Ź Any participants who are willing to participate in 
later focus groups will be given a focus group pack 
containing an invite letter, participant focus group 
information leaflet, expression of interest form and a 
prepaid envelope.
 Ź The clinical pharmacist will then add the patient ID 
code to the ECG and forward it to the study cardiolo-
gist via the  NHS. net email system. All ECGs (normal, 
AF or unclassified/unreadable) will be over read 
by the cardiologist and their result returned within 
72 hours to the study team. All ECGs recorded will be 
uploaded to patient’s medical records. The pharma-
cists detecting atrial fibrillation (PDAF) study team 
will collate all the results from the cardiologist and 
forward a list of patient ID numbers that require 
follow-up and the type of follow-up required (eg, 
12-lead ECG) to the practice. All patient interventions 
are organised by the GP practice in accordance with 
normal practice procedure.
 Ź The PDAF study team will follow-up all patients given 
an AF diagnosis (new or existing) by the cardiolo-
gist to ensure they have been offered a 12-lead ECG 
and appropriate treatment from their practice. From 
those identified patients, enhanced demographic 





HAS-BLED scores, medication history and AF treat-
ment) will be collated.
Primary outcomes
To determine the accuracy and reliability of the clinical 
pharmacist identifying pulse irregularities, when using 
pulse palpation, when compared with the single-lead 
ECG.
To determine accuracy and ability of the clinical phar-
macist to record and interpret a single-lead ECG, using 
the AliveCor Kardia Mobile device, when compared with 
the cardiologist interpretation of the ECG.
secondary outcomes
The level of agreement of the cardiologist’s interpreta-
tion of the ECG compared with that of the device’s auto-
mated algorithm.
The proportion of people with newly identified AF as 
confirmed by the cardiologist’s review of the single-lead 
ECG.
The proportion of newly diagnosed patients that 
remain in AF by the time of their follow-up 12-lead ECG.
The proportion of participants, newly diagnosed with 
AF that have pre-existing chronic conditions (eg, hyper-
tension, diabetes and kidney disease) as confirmed by 
their medical records.
Evaluation of the feasibility of screening for AF by prac-
tice-based clinical pharmacist at influenza vaccination 
clinics, using patient and HCP questionnaires.
Establish the financial impact of the proposed screening 
strategy on the NHS and adult social care resources using 
the National Institute for Health and Care Excellence 
(NICE) cost–utility model.
Quantitative data analysis
Any missing index test data will be excluded from the 
final analysis without data imputation. Participants with 
Figure 3 AliveCor Kardia Mobile single-lead handheld ECG 
(Image used with permission from AliveCor).
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indeterminate index or reference test data will be offered 
a 12-lead ECG follow-up. For single-lead ECG interpre-
tation, the diagnostic accuracy of the clinical pharmacist 
and the in-built device’s algorithm will be compared with 
the scores of the cardiologist using an appropriate paired 
categorical data test (eg, McNemar’s), where two-tailed 
p values of <0.05 will be considered significant. The 
accuracy of the palpation test will be compared with the 
cardiologist’s scores of ECG regularity from the AliveCor 
Kardia Mobile ECG recording, again using McNemar’s 
paired categorical data test. The level of inter-rater agree-
ment between the pharmacist’s, device’s and cardiolo-
gist’s interpretations will be determined using Cohen’s 
kappa statistic, where two-tailed p values of <0.05 will be 
considered significant.
To quantify the accuracy of detection of genuine 
episodes of AF, primary analysis will be conducted using 
IBM Statistical Package for Social Sciences (SPSS V.24). 
Episodes of AF will be expressed as true positives divided 
by the total number screened with accompanying 95% 
CIs.
Analysis of the potential moderating effects of demo-
graphic factors such as age, gender or AF risk factors, 
as well as the difference between sample groups will 
be performed using multivariate Poisson regression. 
Two-tailed p values of <0.05 will be considered significant.
A detailed evaluation of the screening process will be 
undertaken to ascertain the opinions and perceptions of 
the patients, clinical pharmacists, cardiologist, GPs and 
practice staff in relation to the PDAF screening protocol. 
All patient participants will be encouraged to fill in an 
anonymous participant satisfaction questionnaire, imme-
diately after they have been screened. The pharmacists 
and GPs will be asked to complete separate question-
naires postscreening to capture initial feedback and to 
inform the subsequent focus groups.
For cost analysis, the NICE costing report for the 
management of AF will be used as a platform.32 The 
costs for screening, treatment and adverse events will 
be adopted and adjusted for the UK inflation in 2017 
(average inflation rate 1.74%). The screening costs per 
patient will take into consideration the acquisition of 
single-lead ECG devices and the cost of the clinical phar-
macist’s time (average appointment time of 10 min). In 
addition each new AF diagnosis will include the cost of a 
12-lead ECG and consultation with GP and the yearly anti-
coagulation and monitoring costs as proposed by NICE.2
Qualitative data
A computer database (SPSS V.24) will be developed for 
responses to completed questionnaires. A 10% quality 
check of the database will be carried out by a member of 
the team prior to analysis. The data will be analysed using 
descriptive statistics.
Focus groups will also be used to explore in depth the 
patient’s views and experience of the screening process, 
building on the data collected from patient question-
naires. These will be undertaken 1–3 months after the 
screening clinics. Focus groups with HCPs and support 
staff from GP practices will also be used to explore the 
acceptability and feasibility of adopting this screening 
service in the future. Barriers and enablers to implemen-
tation will be identified.
Interviews will be digitally recorded and transcribed. 
Data analysis will focus on Flick’s approach51 using the 
development of predetermined themes connected to the 
interview schedule. NVIVO 10 will be used to facilitate 
this process.
Ethics and dissemination
This protocol was approved on 31 October 2017 by the 
London–Riverside Research Ethics committee and NHS 
Health Research Authority IRAS. The study will be 
submitted for site specific assessment at each partici-
pating site. The study will be conducted in accordance 
with the recommendations for physicians involved in 
research on human subjects adopted by the 18th World 
Medical Assembly, Helsinki 1964 and later revisions. 
The findings of this study will be disseminated through 
forums including, but not limited to, peer-reviewed jour-
nals, national and international conferences.
dIsCussIon
The NHS  Five Year Forward View is to provide integrated 
care for patients with a focus on prevention of ill health, 
in order to keep the general public well.46 However, prob-
lems with patient access to general practice services and 
heavy GP workloads mean that attention is being shifted 
to other HCPs, with pharmacists being identified as an 
underused resource that could assist GPs in delivering this. 
This has led to heavy investment by NHS England into the 
‘Clinical Pharmacists in General Practice Scheme’, a pilot 
study designed to assess the role of the clinical pharmacist 
based within GP practices.48
This is a multisite research healthcare study between 
academics at the University of Kent, GPs in primary care 
and a consultant clinician in secondary care, designed to 
explore the feasibility of using clinical pharmacists based 
within GP practices, to accurately screen and diagnose 
patients with AF using a simple pulse check and a single-
lead ECG, during the influenza season, in accordance 
with the Medical Research Council’s framework for 
complex interventions.52 We believe that if successful, 
this comprehensive AF screening strategy will provide 
a relatively inexpensive mechanism, that capitalises on 
existing healthcare infrastructure within general prac-
tice, to reduce AF-associated stroke (through early AF 
diagnosis and subsequent oral anticoagulant manage-
ment, where appropriate) and raise general awareness 
of AF among the general population and healthcare 
practitioners. As a consequence, this will improve patient 
outcomes, benefit healthcare and social care systems, 
while minimising the associated work load for GPs and 
clinicians.
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study status
We began recruitment in November 2017.
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